Navigation Links
Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator

    Phase 1 healthy volunteer study of IMX942 will provide human safety and
    pharmacodynamic data

VANCOUVER, April 28 /PRNewswire/ - Inimex Pharmaceuticals is pleased to announce that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase 1 safety study of IMX942 being performed for Inimex in Montreal with the approval of Health Canada.

"With this transition of IMX942 into clinical development, we are looking forward to demonstrating the safety and biological effects of our IDR drugs in humans," explains Dr. John R. North, President and CEO of Inimex Pharmaceuticals, Inc. "We are excited that we will soon be in a position to test IMX942, the first of this truly innovative new class of drugs, in patients at risk of infection; we expect to launch the first Phase 2a study during 2010 in the USA under an Investigational New Drug (IND) application."

Inimex Pharmaceuticals secured US$22 Million in Series B venture financing in May 2008, providing the resources to enable the company to conduct the first clinical trials of an IDR drug in patients and to evaluate IDRs in a broad range of disease models. Morningside Venture Investments Ltd. led the Series B syndicate, joined by Astellas Venture Management LLC, BC Advantage Funds (VCC) Ltd., BDC Capital Inc., British Columbia Discovery Fund (VCC) Inc., Canadian Medical Discoveries Fund, Inc., managed by JovInvestment Management, Inc., Roche Venture Fund, and Working Opportunity Fund (EVCC) Ltd., managed by GrowthWorks Capital Ltd.

About IMX942

IMX942 is the first of a new class of drugs known as Innate Defense Regulators, which modulate innate defenses to improve survival, reduce bacterial infections and suppress inflammation. IMX942 is a small, proprietary, fully synthetic peptide that binds to an intracellular adaptor protein and modifies the signaling network downstream of TLR, TNF, and IL-1 receptors. IMX942 has no direct anti-bacterial activity but can control the outcome of infections caused by a broad spectrum of pathogens; in future clinical studies it will be developed for control of infections in high risk patients in the hospital setting.

About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Inimex' first in class products show promise for the safe and effective treatment of a broad spectrum of serious medical conditions, including infectious diseases and inflammatory disorders. For more information, please visit

SOURCE Inimex Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:10/13/2015)... SPRINGS, Florida , October 13, 2015 ... AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ), and ... ARRY ), Avanex Life Sciences Corp. (OTCQX: AVXLD), ... Pharmaceuticals, Inc. (NASDAQ: PGNX ) --> ... and the biotech industry can potentially lead to advancements ...
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
(Date:10/13/2015)... ... ... Proove Biosciences, a commercial and research leader ... Medicine of the University of Southern California (USC) Pain Center to study ... Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one of ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
Breaking Biology Technology:
(Date:10/12/2015)... 9, 2015 Research and Markets ( ... new report "Biometrics: Market Shares, Strategies, and Forecasts, ... --> --> The study is ... market segment. Research represents a selection from the mountains ... market materials, with selections made by the most senior ...
(Date:10/8/2015)... Calif. , Oct. 8, 2015 ... of human interface solutions, announced today that it ... of fiscal 2016 on Thursday, October 22, 2015, ... host a corresponding conference call for analysts and ... during which management may discuss forward-looking information.    ...
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
Breaking Biology News(10 mins):